Drug Trial Radar · NCT05337657
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 2, 2021
Primary completion
Dec 12, 2023
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- Genor Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer
Conditions
- Advanced Breast Cancer
Interventions
GB491+LetrozoleDrug
Drug:The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: During Cycle 1 (up to 28 days)
- AETime frame: From Baseline until 30 days after the last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.